However, the populations evaluated in these clinical studies and in the present analysis did not align with the recommended population for GLP-1 receptor agonists in the current NICE guidelines, which indicate GLP-1 receptor agonists as part of triple therapy for people with type 2 diabetes with a BMI over 35 kg/m2, for those whom insulin therapy would have significant occupational implications, or where weight loss would benefit other obesity-related comorbidities [11]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.